Skip to main content

Cellectar Biosciences, Inc.

CLRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001279704

No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cellectar Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cellectar Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cellectar Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Loren StefanOther: Consultant–Jul 10, 20261
Kolean Chad JCFO6,418Jul 8, 20261
Driscoll Frederick WDirector19,417Jul 8, 20261
Chanan-Khan AsherDirector–Jul 8, 20261
Caruso James VPresident & CEO20,318Jul 8, 20262
Gu AndrewDirector–Jul 8, 20261
Longcor JarrodChief Operating Officer20,451Jul 8, 20262
Swirsky Douglas JDirector25,000Jul 8, 20261
Neis JohnDirector10IndirectJul 8, 20262
Lea Darrell ShaneChief Commercial Officer39,599Jun 18, 20240
Shustov AndreiSenior Vice President, Medical55,038Jun 18, 20240
Elefant DovChief Financial Officer–Jan 27, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 11, 2026 (view filing)8:07 PM ETMay 74 daysLongcor JarrodChief Operating OfficerPPurchase+8.68K$2.88+$25.0K+73.7%20.5K after
May 11, 2026 (view filing)8:07 PM ETMay 74 daysLongcor JarrodChief Operating OfficerPPurchase+26.0K$0.01+$260.4–36.1K afterDerivative
May 11, 2026 (view filing)8:05 PM ETMay 74 daysCaruso James VChief Executive OfficerPPurchase+8.68K$2.88+$25.0K+74.6%20.3K after
May 11, 2026 (view filing)8:05 PM ETMay 74 daysCaruso James VChief Executive OfficerPPurchase+26.0K$0.01+$260.4–36.1K afterDerivative
Dec 16, 2025 (view filing)Dec 124 daysNeis JohnDirectorSSale−198$3.70−$732.6−95.2%10 after
Jul 3, 2025 (view filing)8:02 AM ETJul 21 dayCaruso James VChief Executive OfficerPPurchase+10.0K$4.99+$49.9K+610.5%11.6K after
Jul 3, 2025 (view filing)8:02 AM ETJul 21 dayCaruso James VChief Executive OfficerPPurchase+10.0K$0.01+$100–10.0K afterDerivative
Jul 3, 2025 (view filing)8:01 AM ETJul 21 dayLongcor JarrodChief Operating OfficerPPurchase+10.0K$4.99+$49.9K+361.3%12.8K after
Jul 3, 2025 (view filing)8:01 AM ETJul 21 dayLongcor JarrodChief Operating OfficerPPurchase+10.0K$0.01+$100–10.0K afterDerivative
Jul 3, 2025 (view filing)8:00 AM ETJul 21 dayKolean Chad JChief Financial OfficerPPurchase+5.00K$4.99+$24.9K+352.6%6.42K after
Jul 3, 2025 (view filing)8:00 AM ETJul 21 dayKolean Chad JChief Financial OfficerPPurchase+5.00K$0.01+$50–5.00K afterDerivative
Mar 12, 2025 (view filing)9:44 PM ETJan 1061 daysLateLongcor JarrodChief Operating OfficerPPurchase+30.0K$0.28+$8.40K+56.5%83.1K after
Sep 14, 2021 (view filing)Sep 14Same daySwirsky Douglas JDirectorPPurchase+25.0K$1.04+$26.0KNew position25.0K after
Sep 7, 2021 (view filing)Sep 34 daysDriscoll Frederick WDirectorPPurchase+19.4K$1.04+$20.2KNew position19.4K after